Biotech Values

[jq1234]

Yes, I was really surprised to see the PR today. I assume it has a lot to do with this:

the Janssen AI and Pfizer Joint Steering Committee for the AIP has decided that participants from this study who enrolled in a follow-on extension study will no longer receive doses of bapineuzumab.

I think PFE most likely felt they had obligation to release the result now, NOT until Sept.